- Home
- FMBH vs ANAB Comparison
FMBH vs ANAB Comparison
Compare FMBH & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMBH
- ANAB
- Stock Information
- Founded
- FMBH 1865
- ANAB 2005
- Country
- FMBH United States
- ANAB United States
- Employees
- FMBH N/A
- ANAB N/A
- Industry
- FMBH Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- FMBH Finance
- ANAB Health Care
- Exchange
- FMBH Nasdaq
- ANAB Nasdaq
- Market Cap
- FMBH 881.6M
- ANAB 759.5M
- IPO Year
- FMBH N/A
- ANAB 2017
- Fundamental
- Price
- FMBH $36.70
- ANAB $15.85
- Analyst Decision
- FMBH Buy
- ANAB Buy
- Analyst Count
- FMBH 5
- ANAB 11
- Target Price
- FMBH $44.00
- ANAB $42.67
- AVG Volume (30 Days)
- FMBH 53.7K
- ANAB 635.1K
- Earning Date
- FMBH 01-31-2025
- ANAB 03-10-2025
- Dividend Yield
- FMBH 2.62%
- ANAB N/A
- EPS Growth
- FMBH N/A
- ANAB N/A
- EPS
- FMBH 3.24
- ANAB N/A
- Revenue
- FMBH $316,387,000.00
- ANAB $57,172,000.00
- Revenue This Year
- FMBH N/A
- ANAB $229.13
- Revenue Next Year
- FMBH $4.32
- ANAB N/A
- P/E Ratio
- FMBH $11.31
- ANAB N/A
- Revenue Growth
- FMBH 22.37
- ANAB 282.17
- 52 Week Low
- FMBH $28.86
- ANAB $12.51
- 52 Week High
- FMBH $43.86
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- FMBH 44.16
- ANAB 48.16
- Support Level
- FMBH $36.09
- ANAB $14.76
- Resistance Level
- FMBH $37.44
- ANAB $15.63
- Average True Range (ATR)
- FMBH 0.90
- ANAB 0.99
- MACD
- FMBH 0.18
- ANAB 0.53
- Stochastic Oscillator
- FMBH 77.75
- ANAB 89.66
About FMBH First Mid Bancshares Inc.
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. It also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).